WO2010129860A3 - Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof - Google Patents

Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof Download PDF

Info

Publication number
WO2010129860A3
WO2010129860A3 PCT/US2010/034022 US2010034022W WO2010129860A3 WO 2010129860 A3 WO2010129860 A3 WO 2010129860A3 US 2010034022 W US2010034022 W US 2010034022W WO 2010129860 A3 WO2010129860 A3 WO 2010129860A3
Authority
WO
WIPO (PCT)
Prior art keywords
copd
pulmonary disease
chronic obstructive
obstructive pulmonary
targeting
Prior art date
Application number
PCT/US2010/034022
Other languages
French (fr)
Other versions
WO2010129860A2 (en
Inventor
Serge Patrick Nana-Sinkam
Philip T. Diaz
Michael E. Ezzie
Original Assignee
The Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Ohio State University Research Foundation filed Critical The Ohio State University Research Foundation
Priority to EP10772878A priority Critical patent/EP2427574A2/en
Priority to CA2761411A priority patent/CA2761411A1/en
Priority to US13/319,217 priority patent/US20120264626A1/en
Publication of WO2010129860A2 publication Critical patent/WO2010129860A2/en
Publication of WO2010129860A3 publication Critical patent/WO2010129860A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

A method for diagnosing and staging of chronic obstructive pulmonary disease (COPD) includes measuring expression of one or more miRNAs levels in a subject suspected of suffering from COPD.
PCT/US2010/034022 2009-05-08 2010-05-07 Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof WO2010129860A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10772878A EP2427574A2 (en) 2009-05-08 2010-05-07 Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
CA2761411A CA2761411A1 (en) 2009-05-08 2010-05-07 Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
US13/319,217 US20120264626A1 (en) 2009-05-08 2010-05-07 MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17679409P 2009-05-08 2009-05-08
US61/176,794 2009-05-08
US17970209P 2009-05-19 2009-05-19
US61/179,702 2009-05-19

Publications (2)

Publication Number Publication Date
WO2010129860A2 WO2010129860A2 (en) 2010-11-11
WO2010129860A3 true WO2010129860A3 (en) 2014-03-27

Family

ID=43050897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/034022 WO2010129860A2 (en) 2009-05-08 2010-05-07 Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof

Country Status (4)

Country Link
US (1) US20120264626A1 (en)
EP (1) EP2427574A2 (en)
CA (1) CA2761411A1 (en)
WO (1) WO2010129860A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341145A1 (en) * 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
EP2946014A2 (en) 2013-01-17 2015-11-25 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3461904A1 (en) 2014-11-10 2019-04-03 ModernaTX, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
KR101693996B1 (en) 2015-05-22 2017-01-06 강원대학교산학협력단 Use of Micro RNAs of miR-3615, miR-5701, miR-5581-3p, miR-4792 and miR-2467-5p for Diagnosis of Chronic Obstructive Pulmonary Disease
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017158152A1 (en) * 2016-03-17 2017-09-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. Diagnosis of chronic obstructive pulmonary disease (copd)
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulated biocircuit systems
RU2769316C2 (en) 2016-05-18 2022-03-30 МОДЕРНАТиЭкс, ИНК. Polynucleotides coding interleukin-12 (il12), and applications thereof
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3478313B1 (en) 2016-06-29 2022-05-04 CRISPR Therapeutics AG Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
CA3029119A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
EP3481857A1 (en) 2016-07-06 2019-05-15 Crispr Therapeutics AG Materials and methods for treatment of pain related disorders
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
JP2019532657A (en) 2016-10-26 2019-11-14 モデルナティーエックス， インコーポレイテッド Messenger ribonucleic acid for enhancing immune response and method of use thereof
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN117224710A (en) 2017-02-01 2023-12-15 莫得纳特斯公司 Immunomodulatory therapeutic MRNA compositions encoding mutant peptides that activate oncogenes
US20200040061A1 (en) 2017-02-22 2020-02-06 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
US20200216857A1 (en) 2017-02-22 2020-07-09 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585895A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Compositions and methods for gene editing
US11559588B2 (en) 2017-02-22 2023-01-24 Crispr Therapeutics Ag Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
US11407997B2 (en) 2017-02-22 2022-08-09 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
MA50877A (en) 2017-11-21 2020-09-30 Bayer Healthcare Llc MATERIALS AND METHODS FOR THE TREATMENT OF AUTOSOMIC DOMINANT PIGMENTAL RETINITIS
JP7402163B2 (en) 2017-12-21 2023-12-20 クリスパー セラピューティクス アーゲー Materials and methods for the treatment of Usher syndrome type 2A
EP3728595A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
GB201800533D0 (en) * 2018-01-12 2018-02-28 Imperial Innovations Ltd Accelerated aging biomarker and target
CA3089117A1 (en) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
EP3773745A1 (en) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger rna comprising functional rna elements
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3113651A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
BR112021014845A2 (en) 2019-01-31 2021-11-03 Modernatx Inc Lipid Nanoparticle Preparation Methods
JP2022524081A (en) 2019-03-08 2022-04-27 オブシディアン セラピューティクス， インコーポレイテッド Human Carbonic Amhydrase 2 Compositions and Methods for Adjustable Control
EP3986480A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Messenger rna comprising functional rna elements and uses thereof
WO2020263883A1 (en) 2019-06-24 2020-12-30 Modernatx, Inc. Endonuclease-resistant messenger rna and uses thereof
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
KR20220133957A (en) 2020-01-31 2022-10-05 모더나티엑스, 인크. Method for preparing lipid nanoparticles
WO2022020811A1 (en) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Lipidnanoparticle comprising modified nucleotides
CA3190790A1 (en) 2020-08-06 2022-02-10 Modernatx, Inc. Methods of preparing lipid nanoparticles
KR20230129479A (en) 2021-01-08 2023-09-08 스트랜드 세러퓨틱스 인코포레이티드 Expression constructs and uses thereof
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
CN114480612B (en) * 2021-11-26 2024-04-26 中山大学 Application of exosome miR-654-5p in bronchoalveolar lavage fluid
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
WO2024026487A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
WO2024026482A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099196A1 (en) * 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US20080176766A1 (en) * 2004-11-12 2008-07-24 David Brown Methods and compositions involving mirna and mirna inhibitor molecules
US20080182245A1 (en) * 2004-05-28 2008-07-31 David Brown Methods and Compositions Involving MicroRNA
US20090023594A1 (en) * 2006-11-29 2009-01-22 Exiqon A/S Reagents for labelling nucleic acids and uses thereof
US20090061424A1 (en) * 2007-08-30 2009-03-05 Sigma-Aldrich Company Universal ligation array for analyzing gene expression or genomic variations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182245A1 (en) * 2004-05-28 2008-07-31 David Brown Methods and Compositions Involving MicroRNA
US20080176766A1 (en) * 2004-11-12 2008-07-24 David Brown Methods and compositions involving mirna and mirna inhibitor molecules
US20070099196A1 (en) * 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US20090023594A1 (en) * 2006-11-29 2009-01-22 Exiqon A/S Reagents for labelling nucleic acids and uses thereof
US20090061424A1 (en) * 2007-08-30 2009-03-05 Sigma-Aldrich Company Universal ligation array for analyzing gene expression or genomic variations

Also Published As

Publication number Publication date
CA2761411A1 (en) 2010-11-11
US20120264626A1 (en) 2012-10-18
EP2427574A2 (en) 2012-03-14
WO2010129860A2 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
WO2010129860A3 (en) Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
IL257739B (en) Methods for detecting signatures of disease or conditions in bodily fluids
EP2364367B8 (en) Method utilizing microrna for detecting interstitial lung disease
WO2010099342A3 (en) Methods of detecting lung cancer
ZA201203010B (en) Diagnostic methods for determining prognosis of non-small cell lung cancer
EP2262574A4 (en) Verification system for on-line gamers performing automatic verification of game results
WO2008109773A3 (en) Chronic obstructive pulmonary disease susceptibility and related compositions and methods
WO2012025892A3 (en) Apparatus and method for diagnosing obstructive sleep apnea
BRPI1012644A2 (en) apparatus and method of measuring a biometric marker for exhaled air condensate.
EP2470897A4 (en) Mirna biomarkers of lung disease
WO2009102930A3 (en) Method and system for measuring tissue damage and disease risk
WO2012094643A3 (en) Esophageal cytokine expression profiles in eosinophilic esophagitis
WO2010056737A3 (en) Methods and compositions involving mirnas in cancer stem cells
EP2381844A4 (en) Methods and devices for determining pulmonary measurements
IL208366A0 (en) Compositions and methods for treating and diagnosing asthma
IL210952A0 (en) Methods and compositions for detection of a pathogen, disease, medical condition, or biomarker thereof
PL2413902T3 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
IL214301A (en) Method for amplification of microrna, a method for measuring the amount of a target microrna and a kit for detecting at least one target microrna
WO2010103388A3 (en) Methods using axl as a biomarker of epithelial-to-mesnchymal transition
WO2012129237A3 (en) Therapeutic agent for emphysema and copd
HK1197274A1 (en) Micro-rna biomarkers for identifying risk of and/or for diagnosing lung tumour and pharmaceutical compositions thereof / rna
WO2010034794A3 (en) Methods and kits for the diagnosis and the staging of colorectal cancer
SG10201600502XA (en) Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
WO2013040251A8 (en) Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
ZA201203011B (en) Diagnostic methods for determining prognosis of non-small cell lung cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10772878

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2761411

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010772878

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13319217

Country of ref document: US